Immunome IMNM Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunome's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunome's operating lease right-of-use asset amortization?
- Immunome (IMNM) reported operating lease right-of-use asset amortization of $150K in Q1 2026.
- How has Immunome's operating lease right-of-use asset amortization changed year-over-year?
- Immunome's operating lease right-of-use asset amortization increased by 30.4% year-over-year, from $115K to $150K.
- What is the long-term trend for Immunome's operating lease right-of-use asset amortization?
- Over 3 years (2022 to 2025), Immunome's operating lease right-of-use asset amortization has grown at a 32.8% compound annual growth rate (CAGR), from $209K to $489K.